MedTrace Logo

Tauropace to Prevent Cardiac Implantable Device Infections in Heart Failure Patients

NCT05103267 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2022-11-14

No results posted yet for this study

Summary

The main purpose of the study is to evaluate the ability of the Tauropace to reduce major cardiac implantable electronic device (CIED) infections through 12-months post-procedure following CIED in heart failure participants. The secondary endpoint is to prospectively characterize the performance of Tauropace in participants whose CIED system includes a transvenous RV defibrillation lead.

Conditions

  • Infection Cardiac
  • Heart Failure
  • Cardiac Implantable Electronic Device Infections
  • High Risk

Interventions

DEVICE

Tauropace

TauroPace™ contains disinfecting substances to eradicate environmental microbial contamination on the surface of cardiac implantable electronic devices (CIEDs). The surface of the CIED is moistened with TauroPace™ during the implantation procedure to create a hostile environment on the surface of the CIED.

Sponsors & Collaborators

  • Federico II University

    lead OTHER

Principal Investigators

  • Antonio Rapacciuolo, MD, PhD · Federico II, Naples

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-06
Primary Completion
2023-06-06
Completion
2024-06-06

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05103267 on ClinicalTrials.gov